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Biallelic Mutations in TMEM126B Cause Severe
Complex I Deficiency with a Variable Clinical Phenotype
Charlotte L. Alston,1,22 Alison G. Compton,2,3,22 Luke E. Formosa,4,22 Valentina Strecker,5
Monika Ola´hova´,1 Tobias B. Haack,6,7 Joe´l Smet,8 Katrien Stouffs,9 Peter Diakumis,10 El _zbieta Ciara,11
David Cassiman,12 Nadine Romain,13 John W. Yarham,1 Langping He,1 Boel De Paepe,8
Arnaud V. Vanlander,8 Sara Seneca,9 Rene´ G. Feichtinger,14 Rafal P1oski,15 Dariusz Rokicki,16
Ewa Pronicka,11,16 Ronald G. Haller,13,17 Johan L.K. Van Hove,12,18 Melanie Bahlo,10,19
Johannes A. Mayr,14 Rudy Van Coster,8 Holger Prokisch,6,7 Ilka Wittig,5,20,21 Michael T. Ryan,4
David R. Thorburn,2,3,23,* and Robert W. Taylor1,23,*
Complex I deficiency is the most common biochemical phenotype observed in individuals with mitochondrial disease. With 44 structural
subunits and over 10 assembly factors, it is unsurprising that complex I deficiency is associated with clinical and genetic heterogeneity.
Massively parallel sequencing (MPS) technologies including custom, targeted gene panels or unbiased whole-exome sequencing (WES)
are hugely powerful in identifying the underlying genetic defect in a clinical diagnostic setting, yet many individuals remain without a ge-
netic diagnosis. These individuals might harbor mutations in poorly understood or uncharacterized genes, and their diagnosis relies
upon characterization of these orphan genes. Complexome profiling recently identified TMEM126B as a component of the mitochondrial
complex I assembly complex alongside proteins ACAD9, ECSIT, NDUFAF1, and TIMMDC1.Here, we describe the clinical, biochemical, and
molecular findings in six cases of mitochondrial disease from four unrelated families affected by biallelic (c.635G>T [p.Gly212Val] and/or
c.401delA [p.Asn134Ilefs*2]) TMEM126B variants. We provide functional evidence to support the pathogenicity of these TMEM126B
variants, including evidence of founder effects for both variants, and establish defects within this gene as a cause of complex I deficiency
in association with either pure myopathy in adulthood or, in one individual, a severe multisystem presentation (chronic renal failure
and cardiomyopathy) in infancy. Functional experimentation including viral rescue and complexome profiling of subject cell lines
has confirmed TMEM126B as the tenth complex I assembly factor associated with human disease and validates the importance of
both genome-wide sequencing and proteomic approaches in characterizing disease-associated genes whose physiological roles have been
previously undetermined.Complex I deficiency is the most common biochemical
phenotype observed in subjects with mitochondrial dis-
ease.1 It can occur as an isolated complex deficiency, where
biochemical assessmentof enzymeactivitiesofother respira-
tory-chain components (complexes II, III, and IV) is normal,
or as part of amultiple-respiratory-chain-complexdeficiency
with the involvement of other parts of the oxidative phos-
phorylation (OXPHOS) system. The latter is suggestive of a
global mitochondrial defect involving, for example, mito-
chondrial maintenance, protein translation, or mitochon-
drial import. Mitochondrial complex I deficiency is pheno-
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syndrome [MIM: 256000]) to pure myopathy and exercise
intolerance.1,2 In cases of isolated complex I deficiency, the
genetic basis can be attributed to defects in the mitochon-
drial DNA (mtDNA) genes encoding seven structural sub-
units, in the nuclear genes encoding any of 37 other struc-
tural subunits, or in the increasing number of ancillary
proteins that are responsible for faithful biogenesis and
assembly of complex I. Suchheterogeneity results in compli-
cated diagnostic pipelines for clinical subjects. Massively
parallel sequencing (MPS) strategies, whether in the form
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Figure 1. Autosomal-Recessive TMEM126B Variants Are Identified in Six Unrelated Subjects from Four Families Affected by an
Isolated Complex I Deficiency
(A) Pedigrees and genotype of affected individuals harboring TMEM126B variants. Subject 1 harbors a homozygous c.635G>T
(p.Gly212Val) TMEM126B variant; his parents and unaffected sister are heterozygous carriers of this variant. Subjects 2 and 3 harbor
compound-heterozygous TMEM126B variants—a paternal c.401delA (p.Asn134Ilefs*2) variant and a maternal c.635G>T (p.Gly212Val)
variant. Subjects 4 and 5 also harbor compound-heterozygous c.401delA (p.Asn134Ilefs*2) and c.635G>T (p.Gly212Val) TMEM126B var-
iants; carrier testing confirmed that the subjects’ mother harbors a heterozygous c.401delA (p.Asn134Ilefs*2) variant, but paternal DNA
(legend continued on next page)
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(e.g.,Ampliseq),4 areprovingextremelyeffectiveatestablish-
ing genetic diagnoses, particularly when mutations occur
within known or candidate disease-associated genes. To
date, mutations have been identified in all seven mtDNA-
encoded structural subunits of complex I and 20 nuclear-
encoded structural genes;5–7 similarly, subjects have been
reported with defects in nine assembly factors.5 However,
even after WES analysis, a significant proportion of subjects
lackageneticdiagnosis—acommonexplanation is that their
mutations affect an uncharacterized protein.8,9 Here, we
describe a cohort of six subjects who all harbor recessivemu-
tations within the gene encoding TMEM126B, a protein
recently identified as a complex I assembly factor by a prote-
omic study of knockdown cell lines.10 Complexome
profiling revealed TMEM126B to be a component of the
mitochondrial complex I assembly (MCIA) complex along-
side proteins ACAD9, ECSIT, NDUFAF1, and TIMMDC1,
thus establishing TMEM126B (MIM: 615533) as a candidate
gene for complex I deficiency.10,11 With access to subjects
harboring putative TMEM126B defects, we provide func-
tional evidence to support the pathogenicity of these
TMEM126B variants, unequivocally establishing this gene
as a cause of complex I deficiency in association with either
a severe multisystem presentation in infancy or pure myop-
athy in later child- or adulthood. This report describes the
clinical, biochemical, and molecular findings in six cases of
TMEM126B-related mitochondrial disease and validates
the importance of proteomic approaches in identifying dis-
ease-associated genes whose physiological roles have been
previously undetermined.
Subject 1 (family 1 subject II-1 in Figure 1A) was born to
American parents without known consanguinity. He pre-
sented in childhood with pure exercise intolerance without
muscle weakness. Exercise (running and swimming) caused
leg fatigue, shortness of breath, and a rapid heart rate, often
provokingvomitingandsevereheadache.Cardiology review
in early adulthood showed normal electrocardiography
(ECG) and echocardiography. Treadmill exercise testing cau-
sed fatigue after 2 min with a heart rate of 180 and elevated
blood lactate (16 mmol/L; normal range < 2.0 mmol/L),
characteristic of mitochondrial dysfunction. He had normal
creatine kinase (CK) levels, and there was no pigmenturia.
Physical examination remains normal at 23 years of age.
Subjects 2 and 3 (family 2 subjects II-1 and II-2, respec-
tively, in Figure 1A) are brothers who were born to non-was unavailable for confirmatory testing. Subject 6 harbors a homoz
ents are carriers, and her unaffected brother does not harbor the mu
(B) Sequencing chromatograms depict the recurrent c.635G>T (p.G
which represent the disease alleles identified in our cohort of six aff
(C) Clustal Omega sequence alignment shows the evolutionary cons
(D) Shared maternal and paternal haplotypes in the region of interest
homozygous region from 91.67 to 91.74 cM, whereas subject 6 has a
The two Belgian sibling pairs (subjects 2 and 3 and subjects 4 and 5)
92.12 cM: blue diagonal shade) and the p.Asn134Ilefs*2 haplotype
haplotypes are shared over the 91.31–92.12 cM region. Boxed white
a different family. The Polish subject 6 shares a ~2.2 Mb (91.31–92.4
~2.5 Mb (90.75–92.12 cM) region with siblings 4 and 5.
The Aconsanguineous parents in Belgium. They presented in
their early teens with exercise-induced dyspnea (subject 2),
exercise intolerance (subjects 2 and 3), and post-exertional
myalgia (subjects 2 and 3). Exertion was often followed by
nausea and vomiting. Now in adulthood, currently aged 40
and 37 years, respectively, subjects 2 and 3 are wheelchair
bound and have significantly impaired muscle strength
affecting the lower limbs, particularly hip flexion and
extension. Strength in the upper limbs is normal. Forced
vital capacity, cardiac ultrasound, and cognitive develop-
ment are normal, and neither subject has epilepsy, neurop-
athy, diabetes, or hearing impairment. Subject 2 has
mild visual impairment (macular and peripheral retinal
pigmentmigration) and hadmild left ventricular hypertro-
phy in his twenties. CK was normal, but blood lactate (2.3–
3.0 mmol/L in subject 2 and 3.2–3.8 mmol/L in subject 3)
and cerebrospinal fluid lactate (5.8 mmol/L in subject 3)
were elevated.
Subjects 4 and 5 (family 3 subjects II-1 and II-2, respec-
tively, in Figure 1A) are affected siblings who were born
in Belgium to unrelated parents with no other children.
Their father died at the age of 47 years and complained
of mild exercise intolerance; their mother is alive and com-
plains of fatigue. Subjects 4 and 5 (currently aged 33 and
30 years, respectively) presented in adolescence with fa-
tigue, exercise intolerance, and exercise-induced nausea.
No other organs are affected, although subject 5 reports
gastrointestinal problems. Cardiac, ophthalmic, and neph-
rologic examination, intellectual capacity, and CK were
normal for both subjects. Cycloergometry (for both sib-
lings) showed very low submaximal andmaximal capacity.
Both subjects are able to walk but cannot ride a bike or run,
and they have reported improvements following co-
enzyme Q supplementation (200 mg/d).
Subject 6 (family 4 subject II-1 in Figure 1A) is female and
the second child of healthy, unrelated parents living in
Poland. She was born at 37 weeks of gestation with a
weight of 2,150 g (third percentile [1.88 SD]) and an
Apgar score of 10. Patent ductus arteriosus and an atrial
septal defect without ventricular hypertrophy were
observed, and transient assisted respiration was required
in the early neonatal period. At the age of 2 months, she
was admitted to the hospital with very poor weight gain
and vomiting, and during this period she went into cardiac
arrest, attributed to gastroesophageal reflux and protractedygous c.635G>T (p.Gly212Val) TMEM126B variant; both her par-
tation.
ly212Val) and c.401delA (p.Asn134Ilefs*2) TMEM126B variants,
ected subjects.
ervation of the p.Gly212 residue (marked with an asterisk).
for subjects 1–6, as inferred by SHAPEIT2. Subject 1 has a ~0.5 Mb
~2 Mb homozygous region from 91.51 to 92.46 cM (blue boxes).
share the p.Gly212Val haplotype over a ~1.75 Mb region (91.31–
over a ~4.6 Mb region (89.35–92.2 cM: red diagonal shade). Both
areas represent regions shared with at least one other allele from
6 cM) p.Gly212Val haplotype region with siblings 2 and 3 and a
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Table 1. Biochemical and Clinical Findings in Individuals with TMEM126B Variants
Subject Details TMEM126B Variants OXPHOS Activities in Skeletal Muscle Clinical Features
ID Sex
cDNA (GenBank: NM_018480.4),
Protein (GenBank: NP_060950.3) RCC
Mean Enzyme
Activity
Absolute
Values
Control Mean
(Reference Range)
Age at
Onset Clinical Course
Other Clinical Features and Relevant
Family History
Subject 1a male c.[635G>T];[635G>T],
p.[Gly212Val];[Gly212Val]
I 36% (Y)b 1.8 5.0 5 0.8 (n ¼ 28) 8 years alive at 21 years exercise intolerance, unable to perform
sustained aerobic exercise, normal strength,
normal ECG and echocardiography,
normal resting lactate, normal CK
II 210% ([[) 4.2 2.0 5 0.6 (n ¼ 44)
III 219% ([[) 23.6 10.8 5 2.3 (n ¼ 29)
IV 218% ([[) 8.5 3.9 5 1.5 (n ¼ 44)
CS 196% ([[) 24.1 12.3 5 2.7 (n ¼ 44)
Subject 2c male c.[401delA];[635G>T],
p.[Asn134Ilefs*2];[Gly212Val]
I 48% (Y)b 14 29 5 13 (n ¼ 30) 12 years alive at 39 years,
wheelchair bound
exercise intolerance, muscle weakness
in lower limbs and pelvis, normal
echocardiography, mild basal increases
of lactate, normal CK, normal
intelligence, retinitis pigmentosa
II 138% 47 34 5 14 (n ¼ 30)
III ND ND 96 5 31 (n ¼ 30)
IV 82% 137 167 5 58 (n ¼ 30)
CS 237% ([[) 412 174 5 70 (n ¼ 30)
Subject 3c male c.[401delA];[635G>T],
p.[Asn134Ilefs*2];[Gly212Val]
I 14% (YY)b 4 29 5 13 (n ¼ 30) 10 years alive at 36 years,
wheelchair bound
clinically affected sibling of subject 2,
exercise intolerance, muscle weakness
in lower limbs and pelvis, normal
echocardiography, mild basal increases
in lactate, normal CK, normal
intelligence, no retinitis pigmentosa
II 179% ([) 61 34 5 14 (n ¼ 30)
III ND ND 96 5 31 (n ¼ 30)
IV 103% 172 167 5 58 (n ¼ 30)
CS 281% ([[) 489 174 5 70 (n ¼ 30)
Subject 4a male c.[401delA];[635G>T],
p.[Asn134Ilefs*2];[Gly212Val]
I 10% (YY)b 3 29 5 13 (n ¼ 30) 8 years alive at 32 years exercise intolerance and fatigue
II 253% ([[) 86 34 5 14 (n ¼ 30)
III 172% ([) 165 96 5 31 (n ¼ 30)
IV 126% 210 167 5 58 (n ¼ 30)
CS 201% ([[) 350 174 5 70 (n ¼ 30)
Subject 5a female c.[401delA];[635G>T],
p.[Asn134Ilefs*2];[Gly212Val]
I 10% (YY)b 3 29 5 13 (n ¼ 30) 15 years alive at 29 years clinically affected sibling of subject 4,
exercise intolerance and fatigue
II 288% ([[) 98 34 5 14 (n ¼ 30)
III 129% 124 96 5 31 (n ¼ 30)
IV 238% ([[) 398 167 5 58 (n ¼ 30)
CS 259% ([[) 451 174 5 70 (n ¼ 30)
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2
2
0
T
h
e
A
m
e
rica
n
Jo
u
rn
a
l
o
f
H
u
m
a
n
G
e
n
e
tics
9
9
,
2
1
7
–
2
2
7
,
Ju
ly
7
,
2
0
1
6
T
a
b
le
1
.
C
o
n
ti
n
u
e
d
S
u
b
je
c
t
D
e
ta
il
s
T
M
E
M
1
2
6
B
V
a
ri
a
n
ts
O
X
P
H
O
S
A
c
ti
v
it
ie
s
in
S
k
e
le
ta
l
M
u
sc
le
C
li
n
ic
a
l
F
e
a
tu
re
s
ID
S
e
x
c
D
N
A
(G
e
n
B
a
n
k
:
N
M
_0
1
8
4
8
0
.4
),
P
ro
te
in
(G
e
n
B
a
n
k
:
N
P
_0
6
0
9
5
0
.3
)
R
C
C
M
e
a
n
E
n
z
y
m
e
A
c
ti
v
it
y
A
b
so
lu
te
V
a
lu
e
s
C
o
n
tr
o
l
M
e
a
n
(R
e
fe
re
n
c
e
R
a
n
g
e
)
A
g
e
a
t
O
n
se
t
C
li
n
ic
a
l
C
o
u
rs
e
O
th
e
r
C
li
n
ic
a
l
F
e
a
tu
re
s
a
n
d
R
e
le
v
a
n
t
F
a
m
il
y
H
is
to
ry
Su
b
je
ct
6
a
fe
m
al
e
c.
[6
3
5
G
>
T
];
[6
3
5
G
>
T
],
p
.[
G
ly
2
1
2
V
al
];
[G
ly
2
1
2
V
al
]
I
1
7
%
(Y
Y
)b
3
1
7
5
8
(n
¼
1
5
)
2
m
o
n
th
s
al
iv
e
at
5
.5
y
ea
rs
m
u
lt
io
rg
an
in
v
o
lv
em
en
t
m
an
if
es
ti
n
g
in
in
fa
n
cy
(r
es
p
ir
at
o
ry
fa
il
u
re
,
ca
rd
io
m
y
o
p
at
h
y,
an
d
re
n
al
ac
id
o
si
s)
,
se
v
er
e
g
ro
w
th
fa
il
u
re
,
ch
ro
n
ic
re
n
al
in
su
ffi
ci
en
cy
,
el
ev
at
ed
se
ru
m
la
ct
at
e
II
1
3
5
%
1
3
1
0
5
3
(n
¼
1
5
)
II
I
6
4
%
5
8
9
0
5
5
2
(n
¼
1
5
)
IV
8
2
%
1
0
1
2
5
9
(n
¼
1
5
)
C
S
2
2
8
%
([
[
)
4
5
8
2
0
0
.9
5
4
8
.5
(n
¼
1
5
)
Fo
r
su
b
je
ct
1
,
re
sp
ir
a
to
ry
-c
h
a
in
e
n
zy
m
e
a
ct
iv
it
ie
s
a
re
e
x
p
re
ss
e
d
a
s
U
/m
in
/g
w
e
t
w
e
ig
h
t.
1
2
Fo
r
su
b
je
ct
s
2
–
6
,
e
n
zy
m
e
a
ct
iv
it
ie
s
a
re
e
x
p
re
ss
e
d
a
s
n
a
n
o
m
o
le
s
o
f
su
b
st
ra
te
/m
in
/m
g
p
ro
te
in
.1
3
T
h
e
fo
llo
w
in
g
a
b
b
re
vi
a
ti
o
n
s
a
re
u
se
d
:
Y
,
d
e
cr
e
a
se
d
;
Y
Y
,
m
a
rk
e
d
ly
d
e
cr
e
a
se
d
;
[
,
in
cr
e
a
se
d
;
[
[
,
m
a
rk
e
d
ly
in
cr
e
a
se
d
;
E
C
G
,
e
le
ct
ro
ca
rd
io
g
ra
p
h
y
;
a
n
d
N
D
,
n
o
t
d
e
te
rm
in
e
d
.
a
In
ve
st
ig
a
te
d
b
y
W
E
S
.
b
B
e
lo
w
th
e
n
o
rm
a
l
ra
n
g
e
.
c
In
ve
st
ig
a
te
d
b
y
ta
rg
e
te
d
g
e
n
e
a
n
a
ly
si
s
(A
m
p
liS
e
q
ca
p
tu
re
o
r
ca
rr
ie
r
te
st
in
g
).
The Arenal failure with severe tubular acidosis (pH 7.21 [normal
range ¼ 7.35–7.43], 13.5 mmol/L NaHCO3 [normal
range ¼ 22.0–26.0 mmol/L], 6.0 mmol/L potassium
[normal range ¼ 3.6–5.8 mmol/L], and 124 mmol/L so-
dium [normal range ¼ 136–145 mmol/L]). Progressive hy-
pertrophic cardiomyopathy, failure to thrive, and elevated
blood lactate (8.1 mmol/L) prompted suspicion of mito-
chondrial disease. Currently aged 6 years, she is in good
general condition and has age-appropriate motor and
mental development but shows chronic renal failure (stage
IV) and a marked growth deficit (5.1 SD). She requires
continuous administration of erythropoietin because of
anemia and is supplemented with citrate and sodium
because of tubular acidosis.
Muscle and/or skin biopsy was performed for each sub-
ject, and biochemical, histochemical, andmolecular inves-
tigations were undertaken (Table 1). Informed consent for
diagnostic and research studies was obtained for all sub-
jects in accordance with the Declaration of Helsinki proto-
cols and approved by local institutional review boards.
Histochemical analysis of all subjects’ muscle biopsy re-
vealed subsarcolemmal accumulation of mitochondria,
suggestive of mitochondrial proliferation and evolving pa-
thology of ragged-red fibers (Figure S1). Biochemical anal-
ysis of muscle respiratory-chain activities revealed a
marked isolated complex I deficiency in all subjects, sug-
gestive of a defect involving mtDNA or a nuclear-encoded
protein implicit in complex I structure or assembly. The
genetic basis was identified by previously described MPS
strategies involving either a custom, targeted AmpliSeq
panel (subjects 2 and 3) or WES (subjects 1 and 4–6) as
described elsewhere.14,15 For all cases, biallelic variants in
TMEM126B (GenBank: NM_018480.4 and NP_060950.3)
were identified—just two TMEM126B genotypes, either a
homozygous c.635G>T (p.Gly212Val) missense variant
(subjects 1 and 6) or a compound-heterozygous c.401delA
(p.Asn134Ilefs*2) and c.635G>T (p.Gly212Val) genotype
(subjects 2–5), account for the clinical phenotype of
each subject in our cohort (Table 1 and Figures 1A and
1B). Where familial samples were available from parents
and unaffected siblings, these variants were found to
segregate with a clinically affected status. The c.401delA
(p.Asn134Ilefs*2) variant is absent from dbSNP, the Na-
tional Heart, Lung, and Blood Institute (NHLBI) Exome
Sequencing Project Exome Variant Server (ESP6500), and
the Exome Aggregation Consortium (ExAC) Browser (as of
February 10, 2016). The c.635G>A (p.Gly212Val) variant
is referenced in dbSNP (rs141542003) and recorded in
ESP6500 (Europeans: 16/8,598 alleles [0.2%]) and the
ExAC Browser (Europeans: 146/72,144 alleles [0.2%];
non-Europeans: 10/38,138 [0.02%]). No homozygous cases
have been recorded (according to ExAC, ESP6500, and
dbSNP data as of February 10, 2016), and subject 1 was
the only individual to have rare potentially pathogenic
biallelic TMEM126B variants in over 7,500 samples
sequenced at the Institute of Human Genetics in Munich
(where the c.635G>A variant was present in 15/15,134merican Journal of Human Genetics 99, 217–227, July 7, 2016 221
alleles [0.1%]). BothTMEM126B variants havebeen submit-
ted to ClinVar (see Accession Numbers).
Because the structure of TMEM126B has not been
solved, in silico modeling of TMEM126B tertiary structure
was performed with I-TASSER,16 Phyre2,17 and RaptorX,18
and although confidence was low for overall structure pre-
dictions, each tool predicted the Gly212 residue to be
located within a helical domain. Glycine, the smallest
amino acid and the only one without a carbon-containing
side chain, is often critical within helices because it
is permissive in structure and allows the helix to twist.
Its substitution for a branched-chain amino acid, such
as valine, is likely to affect the tertiary structure and
thus compromise protein function.19,20 This is corrobo-
rated by in silico prediction tools including SIFT,21
MutationTaster,22 and PolyPhen-2,23 which support a
detrimental effect due to the p.Gly212Val substitution.
Moderate evolutionary conservation of the Gly212
TMEM126B residue was suggested by Clustal Omega align-
ment of Ensembl-derived orthologs (Figure 1C).
Given that just two TMEM126B variants were identified
in our ethnically diverse cohort of subjects (from Belgium,
the United States, and Poland), we performed SNP geno-
typing to investigate a possible founder effect (Figure 1D
and Tables S1 and S2). The most likely haplotype structure
for the subjects was inferred with the SHAPEIT2 algo-
rithm.24 As anticipated, there was evidence of two alleles
shared by state (0.81 cM region from 91.31 to 92.12 cM)
for the Belgian sibling pairs from two apparently unrelated
families (subjects 2 and 3 and subjects 4 and 5). Similarly,
there was a shared haplotype (1.15 cM region from 91.31
to 92.46 cM) between subjects 2 (Belgian) and 6 (Polish),
and this was echoed by a 1.37 cM shared haplotype from
90.75 to 92.12 cM in an analysis involving subjects 4
(Belgian) and 6 (Polish). Together, these data support com-
mon ancestors and the c.401delA (p.Asn134Ilefs*2) and
c.635G>T (p.Gly212Val) variants as founder mutations.
Subject 1, of European-American ancestry, was found to
have a very small homozygosity-by-state (HBS) tract
(0.07 cM, ~500 kb genomic distance), but on a background
suggestive of first-cousin parentage. The homozygous
c.635G>T (p.Gly212Val) variant occurs within the HBS
tract but is intriguingly outside the large identity-by-
descent tracts shared as a result of consanguinity. This sug-
gests that a much more distant inbreeding loop leads to
this HBS tract and that the first-cousin inbreeding loop is
coincidental. The sharing of haplotypes in the cohort of
subjects, and that some individuals share several mega-
bases, suggests founder events for both haplotypes; with
evidence of shorter shared haplotypes, HBS, and a slightly
higher frequency than that of the p.Gly212Val variant,
p.Asn134Ilefs*2 is likely to be the older founder event.
Extensive functional characterization of the identified
TMEM126B variants was undertaken in muscle and fibro-
blast cell lines obtained from subjects 1–3. Blue native
PAGE (BN-PAGE) analysis of fibroblasts from affected
subjects revealed a marked reduction of fully assembled222 The American Journal of Human Genetics 99, 217–227, July 7, 20complex I in supercomplex form (Figure 2A) or holoen-
zyme form (Figure 2B) in subjects 2 and 3, who harbored
a truncating mutation in trans with a p.Gly212Val
missense variant. Conversely, complex I assembly was
normal in fibroblasts from subject 1, suggesting an ability
to function despite the biallelic p.Gly212Val variants
(Figure S1). The accumulation of subcomplexes containing
NDUFS3 in subjects 2 and 3 indicates that the matrix mod-
ule containing NDUFS3 is made but is unable to be added
to the membrane arm. SDS-PAGE and immunoblot anal-
ysis of select complex I subunits revealed strongly reduced
levels in fibroblasts from subject 2 and 3, but not subject 1
(Figure 2C). Subsequent BN-PAGE analysis of muscle from
subject 1 revealed severely diminished levels of fully
assembled complex I (Figure 2D).26 These results support
a deleterious effect and recapitulate the biochemical
enzyme assays in which markedly decreased complex I
levels were observed in fibroblasts from compound-hetero-
zygous subjects, whereas the fibroblasts from subject 1 re-
tained complex I activities within the normal range
(Figure 2E). Functional analysis of fibroblasts and muscle
biopsy from additional individuals, notably subjects 4–6,
revealed similar patterns of pathology (Supplemental
Data). Two-dimensional BN-PAGE of mitochondria-en-
riched pellets from muscle biopsy of subjects 4 and 5 re-
vealed a marked reduction of complex I subunits, whereas
other complexes remained intact (Figure S2). Double
immunofluorescence staining of fibroblasts from subjects
4 and 5 (Figure S3) or subject 6 (Figure S4) revealed
decreased signal of TMEM126B directly (subjects 4 and 5)
or clear evidence of reduced signal of complex I subunits
in the case of subject 6 (NDUFS4 was used as a surrogate
marker of complex I signal) in comparison to age-matched
control subjects. Most noteworthy is the observation of a
complex I biochemical defect in the cells from subject 6,
who like subject 1, was homozygous for the p.Gly212Val
variant yet presented much earlier in life with a more se-
vere clinical phenotype (Table 1).
To provide further evidence that TMEM126B muta-
tions are causative, we performed cellular rescue with
TMEM126B variant 1 (GenBank: NM_018480.4) essen-
tially as described previously4 (Figure 3). Retroviral-medi-
ated expression of TMEM126B in subject 2 fibroblasts
largely restored the levels of assembled complex I (Fig-
ure 3A). In addition, after lentiviral-mediated expression
of TMEM126B, enzyme activities were significantly
increased in fibroblasts re-expressing TMEM126B from sub-
jects 2 and 3, whereas fibroblasts from a healthy control or
subject with recessively inherited, pathogenic FOXRED1
variants (described previously28) showed no increased ac-
tivity (Figure 3B).
TMEM126B was identified as a component of the
MCIA complex, which also comprises the previously
characterized assembly factors ACAD9, ECSIT, and
NDUFAF1.10,29 To gain deeper insight into the molecular
consequences of the subjects’ TMEM126B variants, we
analyzed complex I assembly by complexome profiling.16
Figure 2. Biochemical Analysis of Subject
Samples Demonstrates Tissue-Specific
Complex I Deficiency
(A and B) Mitochondria isolated from
cultured skin fibroblasts of control subjects
and subjects 1–3 were analyzed by BN-
PAGE after solubilization in (A) digitonin
formaintaining supercomplex interactions
or (B) Triton X-100 (TX100) for isolating
holo-complexes according to published
methodologies.25 Immunoblotting was
performed with antibodies as indicated.
The blot probed with an antibody raised
against NDUFS3 revealed the presence of
additional, partially assembled complex I
intermediates in the samples from subjects
2 and 3 (A, indicated by an asterisk).
(C) Mitochondria were isolated as
described in (A) and (B) and analyzed by
SDS-PAGE. Immunoblotting was per-
formed with antibodies against complex I
subunits or control proteins as indicated.
(D) Muscle samples derived from subject 1
and two control subjects were solubilized
in n-dodecyl b-D-maltoside (DDM) and
subjected to BN-PAGE and immunoblot
analysis using antibodies directed to
various OXPHOS complexes as indicated.
(E) Respiratory-chain enzyme activities in
fibroblast mitochondria were assayed spec-
trophotometrically as described12 and ex-
pressed as percentages of residual activity
in relation to citrate synthase for subject 1
(white bars), subject 2 (light-gray bars), and
subject 3 (dark-gray bars). Vertical lines
represent the observed normal ranges for
either 8 (subject 1) or 36 (subjects 2
and 3) normal control cell lines deter-
mined in Newcastle or Melbourne, respec-
tively. The following abbreviation is used:
ND, not detected.As visualized in a heatmap (Figure 4), profiles of protein
abundance confirmed a severe complex I assembly defect
in fibroblasts from subjects 2 and 3 and a concomitant
increase in the amount of free complex III. Prominent
accumulation of a stalled assembly intermediate contain-previously.4 Barplots show complex I (CI) activity, normalized by co
transduction with (gray bars) and without (white bars) wild-type T
transfections5 SEM. *p < 0.05, **p < 0.01.
The Aing subunits of the Q module and assembly factors
NDUFAF3, NDUFAF4, and TIMMDC1 was observed, re-
flecting the 315 kDa subcomplex reported by TMEM126B
siRNA experiments in 143B cells.29 Consistent with
TMEM126B-knockdown cells,10 subject mitochondriaFigure 3. Re-expression of Wild-Type
TMEM126B Can Lead to Increased Com-
plex I Assembly and Activity in Subject
Cells
(A) Wild-type TMEM126B mRNA was
generated by retroviral expression in con-
trol and subject 2 fibroblasts as described
previously.27 After transduction and puro-
mycin selection of cells, whole-cell lysates
were solubilized in 1% Triton X-100 and
analyzed by BN-PAGE and immunoblot-
ting using antibodies against NDUFA9
(complex I) and SDHA (complex II) as a
loading control.
(B) Wild-type TMEM126B mRNA was
generated by lentiviral expression, and ac-
tivities of complexes I and IV were assessed
by enzyme dipstick analyses as described
mplex IV (CIV) activity in control and subject fibroblasts,28 after
MEM126B mRNA. Data shown are means of three independent
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Figure 4. Complexome Profiling of Fibroblasts from Subjects 2 and 3 Identifies Stalled Complex I Assembly Intermediates
Prior to mitochondrial isolation, skin fibroblasts were cultured for 48 hr in medium supplemented with galactose as a carbon source.
Mitochondrial protein complexes were solubilized with digitonin and separated by BN-PAGE.30 Native gels were fixed and stained
with Coomassie and cut into 60 equal fractions; proteins were digested with trypsin and analyzed by quantitative mass spectrometry.
For direct comparison of protein-abundance profiles in control and affected subjects, intensity-based absolute quantification values31
calculated byMaxQuant proteomics software32 were normalized to the maximumover datasets (left part of each sample). Less abundant
complex I assembly intermediates were normalized to themaximumwithin themass region below 1,200 kDa (right part of each sample)
for enabling better visualization within a heatmap. The native masses of gel slices were calibrated by exponential regression using po-
sitions of the human OXPHOS complex in the gel.33 The left lane indicates assembly factors (orange), MCIA components (blue), and
structural subunits of complex I (yellow), complex III (red), and complex IV (green). Abbreviations are as follows: MCIA, mitochondrial
complex I assembly complex; CIII2, complex III dimer; CIV, complex IV; and S, supercomplex containing complex I, a dimer of
complex III, and one to four copies of complex IV.formed a ~200 kDa subcomplex containing ND4 and
NDUFB10, indicating that parts of the membrane arm
can be assembled without a complete MCIA complex.
Recent work on TIMMDC1-knockdown cell lines has sug-
gested that the membrane protein TIMMDC1 connects
the pre-assembled membrane subcomplex via interaction
with MCIA components.11,29 In subject mitochondria,
only low levels of the membrane subcomplex were found
in the large assembly intermediate of 830–1,000 kDa,
reflecting an inefficient connection of the Q module and
membrane modules. In contrast to TMEM126B-knock-
down cells,10 the subject cell lines showed markedly
decreased levels of ECSIT, ACAD9, and NDUFAF1, the re-
maining MCIA components, together with complex I
subunits in a mass region between ~800 and 950 kDa.
The last part of the assembly sequence uses assembly
factor NDUFAF2 and the preassembled NADH dehydroge-
nase module (N module) to complete complex I.34–36
Fibroblasts from both affected subjects showed low
amounts of preformed Nmodule intermediates, indicating
that assembly of the membrane part might control Nmod-224 The American Journal of Human Genetics 99, 217–227, July 7, 20ule assembly such that it does not accumulate in the
affected cells. NDUFAF2 was not detected in a complex
with N module subunits but shifted from ~260 kDa in
control cells to ~230 kDa in affected cells. It is
known that once complex I assembly is completed, all
assembly factors dissociate and leave a fully assembled
complex I.37 In cells from subjects 2 and 3, we identified
minor amounts of ECSIT and ACAD9 still bound in the
native mass region corresponding to supercomplex S1,
containing complexes III and IV. It remains to be further
determined whether these large assembly intermediates
are already part of a supercomplex or co-migrate in this
high-molecular-mass region. Another assembly factor,
FOXRED1, recently identified to exhibit a function in
late-stage assembly,25 was identified as co-migrating with
the large assembly intermediate of ~700–800 kDa in con-
trol fibroblasts. In subjects 2 and 3, FOXRED1 could be
detected only at the electrophoretic front and not in a
complex with complex I subunits, suggesting that the
MCIA complex is a prerequisite for binding and function
in the large intermediate.16
Tissue specificity is a common phenomenon in
OXPHOS disorders,38 but this feature is particularly strik-
ing with the TMEM126B mutations we describe here.
Five of the six subjects have relatively mild symptoms,
confined mostly to myopathy, and all have normal cogni-
tive development despite having a severe complex I defect
in muscle and the fact that TMEM126B appears to be a
ubiquitous complex I assembly factor. All tissues studied
from subjects with TMEM126Bmutations showed some re-
sidual complex I assembly, and the threshold level of com-
plex I activity required by any tissue most likely depends
on factors such as variation in the amounts of subunits
and assembly factors, plus variation in protein turnover
rates and basal and peak energetic demands. Inter-individ-
ual differences were also apparent—all subjects except sub-
ject 1 had amarked complex I defect in skin fibroblasts. We
note that subject 6’s congenital heart defects, low birth
weight, and episode of acute dehydration most likely
contributed to the severity of her symptoms. However,
subjects 1 and 6 are both homozygous for the p.Gly212Val
variant, but fibroblast complex I activity was normal in
subject 1 and deficient in subject 6. Hence, the variation
in outcomes also most likely relates to a combination of
the severity of different mutations and as yet unknown ge-
netic modifiers affecting the biochemical and clinical phe-
notypes. It is also possible that the alternative TMEM126B
isoforms arising through alternative splicing of the
TMEM126B mRNA transcripts might affect the clinical
phenotype. The possibility of pathogenic variants within
the TMEM126B paralog, TMEM126A, was excluded in sub-
ject 6 by analysis of the WES dataset; moreover, optic atro-
phy is a discriminatory feature in cases of TMEM126A
pathology, and this individual has normal visual acuity.
CharacterizationofTMEM126Bafterproteomic screening
and subsequent application of diagnostic MPS strategies
has resulted in the diagnosis of six subjects from four
families affected by TMEM126B-related mitochondrial dis-
ease. Our subjects suggest that a late-onset myopathic
phenotype is the predominant clinical phenotype associ-
ated with TMEM126B defects. Functional experimentation
including lentiviral rescue of subject fibroblasts establishes
TMEM126B as the tenth complex I assembly factor associ-
ated with human disease, and this gene should be consid-
ered in the molecular genetic workup of subjects with
biochemical evidence of an isolated complex I deficiency,
particularly in European populations.Accession Numbers
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